Search results
Results From The WOW.Com Content Network
The merged entity was then named as Zydus Wellness Limited in January 2009. [12] [13] In 2009, the company began manufacturing men's grooming and skincare products. [12] [14] In 2011, Zydus Wellness launched its milk additive brand Actilife. [15] In 2017, Zydus Wellness developed stevia products as part of its sugar substitute business. [16]
Zydus Wellness Limited (NSE:ZYDUSWELL) shares fell 9.7% to ₹1,463 in the week since its latest second-quarter results...
In December 2016, Zydus Discovery DMCC, a research subsidiary Zydus Lifesciences, was cited by the US FDA for deliberately misbranding their flagship product, Saroglitazar—the drug used to treat diabetic dyslipidemia in India. In a 21 December 2016 letter to the company, the US FDA asked it to stop using broad statements, such as the "world's ...
The growth–share matrix [2] (also known as the product portfolio matrix, [3] Boston Box, BCG-matrix, Boston matrix, Boston Consulting Group portfolio analysis and portfolio diagram) is a matrix used to help corporations to analyze their business units, that is, their product lines.
The user status data may include, for example, the severity of a headache. About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical ...
Complan was launched by Glaxo in 1954. As part of Glaxo's Farley Health Products subsidiary, the Complan UK brand was sold to Boots in 1988. In India, Complan remained with Glaxo until 1994, when it was acquired by Heinz, who also acquired the UK brand in the same year.
Also in June 2016 Teva sold two ANDAs to Indian pharmaceutical company Zydus Cadilla, strengthening its US portfolio. [76] On June 21, 2016, American pharmaceutical company Amneal Pharmaceutical previously known as Impax Laboratories bought a portfolio of generic drugs from Teva Pharmaceutical Industries for about $586 million. [ 77 ]
Zydus Lifesciences and Sun Pharmaceuticals have entered an agreement in October 2023 to co-market Desidustat. Sun Pharma will sell the drug as Rytstat, while Zydus will continue to sell it as Oxemia. [6]